|
All Releases
 |
Achillion Announces Additional Positive Top-Line Phase 2 Data for Elvucitabine
Jun 9, 2008
|
11.9 KB |
|
| |
NEW HAVEN, Conn., Jun 9, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced additional positive safety and efficacy results from its ongoing Phase 2 trial studying elvucita...
|
|
Achillion Nominates ACH-1625 as Lead Candidate in Proprietary Program Targeting HCV Protease
Jun 4, 2008
|
10.8 KB |
|
| |
NEW HAVEN, Conn., Jun 4, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of its first clinical candidate from the company's proprietary HCV protease program. The candidate, ACH-1625, is a highly selective inhibitor of HCV NS3 protease.
In preclinical studies, Achillion...
|
|
Achillion to Present At Needham Biotechnology Conference
May 23, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., May 23, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Reports First Quarter 2008 Financial Results
May 7, 2008
|
13.8 KB |
|
| |
NEW HAVEN, Conn., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended March 31, 2008.
For the first quarter of 2008, the Co...
|
|
Achillion and FOB Synthesis Announce Collaboration for the Development of Carbapenem Compounds
Apr 8, 2008
|
11.1 KB |
|
| |
NEW HAVEN, Conn. and KENNESAW, Ga., Apr 8, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) and FOB Synthesis, Inc. today announced that the companies have signed an exclusive agreement granting Achillion worldwide rights for the research, development and commercialization of certain FOB compounds for th...
|
|
Achillion Appoints Gary E. Frashier to Board of Directors
Apr 2, 2008
|
10.5 KB |
|
| |
NEW HAVEN, Conn., Apr 2, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Gary E. Frashier to its Board of Directors. Mr. Frashier, a principal with Ma...
|
|
Achillion to Present At Cowen Healthcare Conference
Mar 14, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Mar 14, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Reports 2007 Fourth Quarter and Year-End Financial Results
Feb 27, 2008
|
16.6 KB |
|
| |
NEW HAVEN, Conn., Feb 27, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and year ended December 31, 2007.
For the full year ended ...
|
|
Achillion to Present At the BIO CEO and Investor Conference
Feb 8, 2008
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Feb 8, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overvi...
|
|
New Data for Achillion's Elvucitabine Demonstrate Drug's Safety, Efficacy and Suitability for Combination Therapy in HIV-Infected Patients
Jan 31, 2008
|
15.4 KB |
|
| |
NEW HAVEN, Conn., Jan 31, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced positive safety and efficacy results from two ongoing Phase 2 clinical trials studying elvucita...
|
|
Achillion Announces Appointment of New Chief Medical Officer
Nov 26, 2007
|
10.4 KB |
|
| |
NEW HAVEN, Conn., Nov 26, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Dr. Elizabeth A. Olek as vice president and chief medical officer. Dr. Olek ...
|
|
Achillion to Present At Upcoming Conferences
Nov 2, 2007
|
9.1 KB |
|
| |
NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presentin...
|
|
Achillion Reports Third Quarter 2007 Financial Results
Nov 2, 2007
|
13.6 KB |
|
| |
NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended September 30, 2007.
For the third quarter of 2007, th...
|
|
Achillion Reports Safety and Potent Antiviral Activity in Topline Results From Elvucitabine Phase 2 Study in HIV-Infected Patients
Oct 15, 2007
|
12.1 KB |
|
| |
NEW HAVEN, Conn., Oct 15, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced preliminary 12-week results from an ongoing Phase 2 clinical trial studying elvucitabine in pat...
|
|
Achillion to Present At the First Annual Maxim Group Growth Conference
Sep 17, 2007
|
8.8 KB |
|
| |
NEW HAVEN, Conn., Sep 17, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overv...
|
|
Achillion Appoints Pharmathene CEO David P. Wright to Board of Directors
Aug 22, 2007
|
10.1 KB |
|
| |
NEW HAVEN, Conn., Aug 22, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of David P. Wright to its Board of Directors. Mr. Wright, who is President and ...
|
|
Achillion Reports 2007 Second Quarter Financial Results
Aug 8, 2007
|
15.1 KB |
|
| |
NEW HAVEN, Conn., Aug 8, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and six months ended June 30, 2007.
For the six months ende...
|
|
Achillion to Host Second Quarter Investor Conference Call On August 8, 2007
Jul 27, 2007
|
8.3 KB |
|
| |
NEW HAVEN, Conn., Jul 27, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals Inc. (Nasdaq:ACHN) expects to release its results for the second quarter ended June 30, 2007 after the market closes on Wednesday, August 8, 2007.
The company will host a conference call to discuss the results at 4:30 PM ET on August 8. The call ...
|
|
Achillion Announces the Promotion of Milind S. Deshpande, Ph.D. to Executive Vice President of Research
Jun 11, 2007
|
10.0 KB |
|
| |
NEW HAVEN, Conn., Jun 11, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Milind Deshpande, Ph.D. has been promoted to Executive Vice President of Research. Dr. Des...
|
|
Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
May 17, 2007
|
10.0 KB |
|
| |
NEW HAVEN, Conn., May 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer, has resigned to accept a senior clinical development position at GlaxoSmithKline. His resignation will become effective on M...
|
|
|
= add release to Briefcase |